CA2234235A1 - Gel formulations containing growth factors - Google Patents
Gel formulations containing growth factorsInfo
- Publication number
- CA2234235A1 CA2234235A1 CA002234235A CA2234235A CA2234235A1 CA 2234235 A1 CA2234235 A1 CA 2234235A1 CA 002234235 A CA002234235 A CA 002234235A CA 2234235 A CA2234235 A CA 2234235A CA 2234235 A1 CA2234235 A1 CA 2234235A1
- Authority
- CA
- Canada
- Prior art keywords
- gel formulations
- growth factors
- gel
- formulations containing
- containing growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Abstract
Gel formulations containing polypeptide growth factors having human mitogenic or angiogenic activity are provided. The gel formulations are useful for topical or incisional wound healing for cutaneous wounds, particularly in the anterior chamber of the eye. The gel formulations also comprise a water soluble, pharmaceutically or ophthalmically compatible polymeric material for providing viscosity within various ranges determined by the application of the gel. The gel formulations provide controlled release and increased contact time of the growth factor to the wound site.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/539,898 | 1995-10-06 | ||
US08/539,898 US5705485A (en) | 1987-09-18 | 1995-10-06 | Gel formulations containing growth factors |
PCT/US1996/015288 WO1997012601A2 (en) | 1995-10-06 | 1996-09-24 | Gel formulations containing growth factors |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2234235A1 true CA2234235A1 (en) | 1997-04-10 |
CA2234235C CA2234235C (en) | 2002-05-14 |
Family
ID=24153118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002234235A Expired - Fee Related CA2234235C (en) | 1995-10-06 | 1996-09-24 | Gel formulations containing growth factors |
Country Status (19)
Country | Link |
---|---|
US (1) | US5705485A (en) |
EP (1) | EP0859596B1 (en) |
JP (1) | JP4001382B2 (en) |
KR (1) | KR100444417B1 (en) |
CN (1) | CN1142791C (en) |
AT (1) | ATE209900T1 (en) |
AU (1) | AU706806B2 (en) |
BR (1) | BR9610790A (en) |
CA (1) | CA2234235C (en) |
CZ (1) | CZ294676B6 (en) |
DE (1) | DE69617723T2 (en) |
DK (1) | DK0859596T3 (en) |
ES (1) | ES2167611T3 (en) |
HU (1) | HU223880B1 (en) |
NO (1) | NO981539L (en) |
PL (1) | PL187174B1 (en) |
PT (1) | PT859596E (en) |
WO (1) | WO1997012601A2 (en) |
ZA (1) | ZA968398B (en) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1171635C (en) * | 1998-03-07 | 2004-10-20 | 株式会社大熊制药 | Topical composition containing human epidermal growth factor |
US20030147860A1 (en) | 2002-02-07 | 2003-08-07 | Marchosky J. Alexander | Compositions and methods for forming and strengthening bone |
DE69936212T2 (en) | 1998-09-04 | 2008-01-24 | Scios Inc., Sunnyvale | Controlled release hydrogel compositions for the administration of growth factors |
US6057280A (en) | 1998-11-19 | 2000-05-02 | Huish Detergents, Inc. | Compositions containing α-sulfofatty acid esters and methods of making and using the same |
DE19925519A1 (en) | 1999-06-04 | 2000-12-07 | Lohmann Therapie Syst Lts | Laminar wound dressing for controlled release of active substance e.g. platelet derived growth factor, includes layer containing polymer and hydrogel as fluid absorber |
AU5624500A (en) * | 1999-06-18 | 2001-01-09 | Collaborative Group, Ltd., The | Hyaluronic acid microspheres for sustained gene transfer |
US8188043B2 (en) * | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
WO2001034214A1 (en) | 1999-11-09 | 2001-05-17 | Denki Kagaku Kogyo Kabushiki Kaisha | Use of soluble cellulose derivative having been made hardly soluble in water and process for producing the same |
DE10048260A1 (en) * | 2000-09-29 | 2002-04-11 | Beiersdorf Ag | Cosmetic or dermatological composition for combating undesirable skin pigmentation, contains aminoguanidine or its derivatives |
US6703039B2 (en) * | 2000-12-06 | 2004-03-09 | Bausch & Lomb Incorporated | Reversible gelling system for ocular drug delivery |
JP4434584B2 (en) * | 2001-01-26 | 2010-03-17 | ジェネティックス ファーマシューティカルズ, インク. | Methods and compositions for promoting angiogenesis |
DE10140623A1 (en) * | 2001-08-18 | 2003-03-06 | Nawa Heilmittel Gmbh | Pharmaceutical preparation for the treatment of wounds |
US6835536B2 (en) * | 2001-08-21 | 2004-12-28 | Micrologix Biotech Inc. | Antimicrobial cationic peptides and formulations thereof |
US7037504B2 (en) * | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
US20080086792A1 (en) | 2006-10-13 | 2008-04-17 | Thomas Charles Kuracina | Method and apparatus for diverting sweat, liquid, moisture or the like from an eye |
JP4489437B2 (en) | 2002-02-21 | 2010-06-23 | エンセル,インコーポレイテッド | Immobilized bioactive hydrogel matrix as a surface coating |
US20030220632A1 (en) * | 2002-05-23 | 2003-11-27 | Wolfgang Strasser | Method of using gel sheets for laser treatment |
CA2499014A1 (en) | 2002-09-16 | 2004-03-25 | Agennix Incorporated | Lactoferrin compositions and methods of wound treatment |
EP2113246B1 (en) * | 2003-08-07 | 2016-06-22 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using the same |
DE602004031303D1 (en) | 2003-12-11 | 2011-03-17 | Teikoku Pharma Usa Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN WOUND |
CN100411615C (en) * | 2003-12-12 | 2008-08-20 | 上海第二医科大学附属瑞金医院 | Effect of aminoguanidine for curing wound surface in refractory to treatment |
WO2005077402A1 (en) * | 2004-02-11 | 2005-08-25 | Virchow Biotech Private Limited | Honey based gel formulations |
CA2574977C (en) * | 2004-07-29 | 2010-01-26 | X-Sten, Corp. | Spinal ligament modification devices |
WO2006036984A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Stand-alone film and methods for making the same |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
EP1904094A2 (en) * | 2005-06-17 | 2008-04-02 | Genentech, Inc. | Use of vegf for wound healing |
WO2007013100A1 (en) * | 2005-07-26 | 2007-02-01 | Virchow Biotech Private Limited | Gel formulation comprising platelet derived growth factor |
WO2007016683A2 (en) | 2005-07-29 | 2007-02-08 | X-Sten, Corp. | Device for resecting spinal tissue |
US20070055263A1 (en) * | 2005-07-29 | 2007-03-08 | X-Sten Corp. | Tools for Percutaneous Spinal Ligament Decompression and Device for Supporting Same |
FR2891149B1 (en) * | 2005-09-26 | 2007-11-30 | Biodex Sarl | PHARMACEUTICAL COMPOSITION WITH A HEALING ACTION COMPRISING A SOLUBLE DEXTRANE DERIVATIVE AND A PLATELET DERIVED GROWTH FACTOR. |
US9278161B2 (en) * | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US20070077302A1 (en) * | 2005-09-30 | 2007-04-05 | Azaam Alli | Methods for stabilizing ophthalmic compositions |
DE102005055275A1 (en) * | 2005-11-17 | 2007-05-24 | Ursapharm Arzneimittel Gmbh & Co. Kg | Phosphate-free pharmaceutical composition and its use |
KR100687281B1 (en) * | 2005-11-30 | 2007-02-27 | 한국과학기술연구원 | Injectable thermosensitive pluronic hydrogels coupled with bioactive materials for tissue regeneration and preparation method thereof |
KR100742313B1 (en) * | 2006-03-21 | 2007-07-24 | 퓨리메드 주식회사 | New gene and polypeptides of platelet derived growth factor b |
US7942830B2 (en) | 2006-05-09 | 2011-05-17 | Vertos Medical, Inc. | Ipsilateral approach to minimally invasive ligament decompression procedure |
KR100784134B1 (en) * | 2006-10-09 | 2007-12-12 | 주식회사 대웅 | Stable liquid compositions for treating mucositis comprising epidermal growth factor |
EP2090314A4 (en) * | 2006-10-26 | 2010-01-13 | Senju Pharma Co | Ophthalmic aqeous liquid preparation |
US8343536B2 (en) | 2007-01-25 | 2013-01-01 | Cook Biotech Incorporated | Biofilm-inhibiting medical products |
EP2114268A4 (en) * | 2007-02-12 | 2010-03-03 | Vertos Medical Inc | Tissue excision devices and methods |
US20090118709A1 (en) * | 2007-11-06 | 2009-05-07 | Vertos Medical, Inc. A Delaware Corporation | Tissue Excision Tool, Kits and Methods of Using the Same |
JP5582711B2 (en) * | 2008-09-25 | 2014-09-03 | 株式会社エー・アイ・システムプロダクト | Lotion |
USD619253S1 (en) | 2008-10-23 | 2010-07-06 | Vertos Medical, Inc. | Tissue modification device |
USD611146S1 (en) | 2008-10-23 | 2010-03-02 | Vertos Medical, Inc. | Tissue modification device |
USD610259S1 (en) | 2008-10-23 | 2010-02-16 | Vertos Medical, Inc. | Tissue modification device |
USD621939S1 (en) | 2008-10-23 | 2010-08-17 | Vertos Medical, Inc. | Tissue modification device |
USD619252S1 (en) | 2008-10-23 | 2010-07-06 | Vertos Medical, Inc. | Tissue modification device |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
CN102548538B (en) * | 2009-09-22 | 2014-03-12 | V生命科学技术有限公司 | Topical formulation for diabetic foot ulcers |
US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
WO2013005235A1 (en) * | 2011-07-06 | 2013-01-10 | Orf Liftaekni Hf | Method of use of stabilised non-plant-derived growth factor in skin care |
EP2776052B1 (en) | 2011-11-02 | 2017-06-14 | Halscion, Inc. | Methods and compositions for wound treatment |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
US9422497B2 (en) | 2012-09-21 | 2016-08-23 | Exxonmobil Research And Engineering Company | Synthetic lubricant basestocks and methods of preparation thereof |
US10376562B2 (en) | 2013-03-15 | 2019-08-13 | The Jackson Laboratory | Methods for promoting wound healing and hair growth comprising GDNF administration |
UA118843C2 (en) | 2013-03-15 | 2019-03-25 | Дженентек, Інк. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
US9675537B2 (en) | 2014-06-30 | 2017-06-13 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
CA2962954A1 (en) | 2014-10-14 | 2016-04-21 | Samuel Lynch | Compositions for treating wounds |
WO2017035280A1 (en) * | 2015-08-24 | 2017-03-02 | Nugene, Inc. | Skin damage healing aids and dressings |
EP3419669A4 (en) * | 2016-02-23 | 2019-10-30 | Matripharm International Inc. | Dual-rate release formulation with high drug loading |
WO2018213795A1 (en) * | 2017-05-18 | 2018-11-22 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted in situ therapeutic delivery of secreted factors from stem cells for treatment of damaged tissue |
KR20200115546A (en) | 2018-01-26 | 2020-10-07 | 제넨테크, 인크. | IL-22 Fc fusion protein and method of use |
BR112020015016A2 (en) | 2018-01-26 | 2020-12-29 | Genentech, Inc. | PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT OF INFLAMMATORY INTESTINAL DISEASE, INHIBITION OF MICROBIAL INFECTION IN THE INTESTINE AND ACCELERATING OR IMPROVING WOUND HEALING |
AU2019226085A1 (en) | 2018-02-21 | 2020-09-17 | Genentech, Inc. | Dosing for treatment with IL-22 Fc fusion proteins |
CN114601959A (en) * | 2020-11-23 | 2022-06-10 | 山东融元康医疗科技有限公司 | Medical skin care dressing and preparation method and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1190361B (en) * | 1985-05-30 | 1988-02-16 | Zambon Spa | PHARMACEUTICAL COMPOSITION IN CREAM FOR DERMAL AND OPHTHALMIC USE |
NZ222413A (en) * | 1986-11-05 | 1991-06-25 | Ethicon Inc | Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser |
US4717717A (en) * | 1986-11-05 | 1988-01-05 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
US5124316A (en) * | 1986-11-14 | 1992-06-23 | President And Fellows Of Harvard College | Method for periodontal regeneration |
US5457093A (en) * | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
NZ226171A (en) * | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
DK0591392T3 (en) * | 1991-06-21 | 1996-09-30 | Genetics Inst | Pharmaceutical formulations of osteogenic proteins |
HUT67319A (en) * | 1991-08-30 | 1995-03-28 | Life Medical Sciences Inc | Compositions for treating wounds |
AU3062392A (en) * | 1991-11-04 | 1993-06-07 | Novo Nordisk A/S | Pdgf gel formulation |
JP3102655B2 (en) * | 1991-12-27 | 2000-10-23 | 住友製薬株式会社 | Ultrasound controlled drug release formulation |
-
1995
- 1995-10-06 US US08/539,898 patent/US5705485A/en not_active Expired - Lifetime
-
1996
- 1996-09-24 PL PL96326064A patent/PL187174B1/en not_active IP Right Cessation
- 1996-09-24 JP JP51430597A patent/JP4001382B2/en not_active Expired - Fee Related
- 1996-09-24 AT AT96935936T patent/ATE209900T1/en not_active IP Right Cessation
- 1996-09-24 WO PCT/US1996/015288 patent/WO1997012601A2/en active IP Right Grant
- 1996-09-24 CA CA002234235A patent/CA2234235C/en not_active Expired - Fee Related
- 1996-09-24 ES ES96935936T patent/ES2167611T3/en not_active Expired - Lifetime
- 1996-09-24 DE DE69617723T patent/DE69617723T2/en not_active Expired - Lifetime
- 1996-09-24 BR BR9610790A patent/BR9610790A/en not_active IP Right Cessation
- 1996-09-24 PT PT96935936T patent/PT859596E/en unknown
- 1996-09-24 CZ CZ19981024A patent/CZ294676B6/en not_active IP Right Cessation
- 1996-09-24 AU AU73707/96A patent/AU706806B2/en not_active Ceased
- 1996-09-24 KR KR10-1998-0702519A patent/KR100444417B1/en not_active IP Right Cessation
- 1996-09-24 HU HU9803002A patent/HU223880B1/en not_active IP Right Cessation
- 1996-09-24 EP EP96935936A patent/EP0859596B1/en not_active Expired - Lifetime
- 1996-09-24 CN CNB961987731A patent/CN1142791C/en not_active Expired - Fee Related
- 1996-09-24 DK DK96935936T patent/DK0859596T3/en active
- 1996-10-04 ZA ZA9608398A patent/ZA968398B/en unknown
-
1998
- 1998-04-03 NO NO981539A patent/NO981539L/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1142791C (en) | 2004-03-24 |
HUP9803002A2 (en) | 1999-04-28 |
PL326064A1 (en) | 1998-08-17 |
ATE209900T1 (en) | 2001-12-15 |
ES2167611T3 (en) | 2002-05-16 |
DE69617723T2 (en) | 2002-05-08 |
US5705485A (en) | 1998-01-06 |
JP4001382B2 (en) | 2007-10-31 |
WO1997012601A3 (en) | 1997-05-01 |
CZ294676B6 (en) | 2005-02-16 |
WO1997012601A2 (en) | 1997-04-10 |
HU223880B1 (en) | 2005-02-28 |
KR19990064041A (en) | 1999-07-26 |
DE69617723D1 (en) | 2002-01-17 |
NO981539L (en) | 1998-06-02 |
AU706806B2 (en) | 1999-06-24 |
PL187174B1 (en) | 2004-05-31 |
AU7370796A (en) | 1997-04-28 |
PT859596E (en) | 2002-05-31 |
DK0859596T3 (en) | 2002-03-04 |
ZA968398B (en) | 1998-04-06 |
HUP9803002A3 (en) | 2001-08-28 |
JPH11512740A (en) | 1999-11-02 |
CZ102498A3 (en) | 1999-08-11 |
KR100444417B1 (en) | 2004-11-03 |
CA2234235C (en) | 2002-05-14 |
EP0859596A2 (en) | 1998-08-26 |
BR9610790A (en) | 1999-07-13 |
NO981539D0 (en) | 1998-04-03 |
CN1211191A (en) | 1999-03-17 |
EP0859596B1 (en) | 2001-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2234235A1 (en) | Gel formulations containing growth factors | |
EP0383363A3 (en) | Use of wound healing agents | |
EP1563844A3 (en) | Wound healing formulations containing human plasma fibronectin | |
CA2180659A1 (en) | Use of a collagen membrane in preparation of an implant for guided tissue regeneration | |
CA2241188A1 (en) | Hydrogel wound dressing and the method of making and using the same | |
WO1999032135A8 (en) | Keratinocyte growth factor-2 formulations | |
EP2258402A3 (en) | Dried composition | |
AU3382995A (en) | Combined preparation for the therapy of immunological diseases | |
CA2329538A1 (en) | Directional endoscopic delivery of material | |
CA2154103A1 (en) | Treatment of Mucous Membrane Disease, Trauma or Condition and for the Relief of Pain | |
CA2200480A1 (en) | New use of prostaglandins | |
CA2031817A1 (en) | Use of thrombospondin to promote wound healing | |
IT1275556B (en) | PROCESS AND PLANT FOR THE DEHYDRATION OF FORAGE, IN PARTICULARLY FOR THE DEHYDRATION OF THE MEDICAL GRASS | |
AU6856194A (en) | Vaginal preparation containing physiologically active peptide | |
AU8064091A (en) | Pharmaceutical preparation | |
CA2283450A1 (en) | Methods for treatment of scar tissue | |
AU5448490A (en) | Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue | |
RU2003337C1 (en) | Wound healing agent | |
CA2334514A1 (en) | Use of a wound dressing in the treatment of acute wounds | |
BG96495A (en) | Aplication of - interferon for the treatment of wounds in autommune vasculitis | |
CA2244679A1 (en) | Tranilast-containing preparation for external application and method of producing the same | |
CA2215200A1 (en) | Biodegradable device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |